相关实验视频

Updated: Jun 15, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

循环瘤DNA在复发性/耐药性扩散性大B细胞淋巴瘤患者中的动态

Yujie Zhong^1,2,3, Johanna Bult^1,3, Nick Veltmaat^1,3

¹Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

British journal of haematology

|December 18, 2025

概括

循环瘤DNA (ctDNA) 分析在复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 中显示出有前途. ctDNA动态可以预测治疗反应并识别最小残留疾病,有助于个性化救援化疗策略.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子诊断学分子诊断学

背景情况:

复发性/耐药性 (R/R) 扩散性大B细胞淋巴瘤 (DLBCL) 的救生化疗有效性有限.
在接受救援化疗的R/R DLBCL患者中,循环瘤DNA (ctDNA) 的数据很少.

研究的目的:

为了研究ctDNA动态作为预后生物标志物的实用性,在R/R DLBCL患者接受救援化疗.
探索ctDNA变化与治疗结果之间的相关性,包括反应率和存活率.

主要方法:

分析了来自29名R/R DLBCL患者的124个血样本,使用低覆盖率的全基因组测序来检测拷贝数变化 (CNA) 和针对单核和多核酸变异 (SNV/MNV) 的定向测序.
评估ctDNA动态,包括基因组改变 (FGA) 分数和变异清除,与临床结果相关.

主要成果:

完全应答率为55%,无进展生存率为31%.
较高的基线FGA和ctDNA水平与治疗失败有关.
低基线FGA与低代谢瘤体积 (MTV) 结合,预测了有利的结果.
在中期评估时ctDNA变异清除与改善的反应相关,而持久性预测失败.
可检测的ctDNA治疗后表明残留疾病最小,并预测复发.

结论:

在R/R DLBCL中,ctDNA分析是一个有价值的预后生物标志物.
ctDNA动态可以指导R/R DLBCL患者的响应适应的治疗策略.
ctDNA作为一种敏感的标记,用于检测最小的残留疾病,告知复发风险.

关键词:

ctDNActDNA是什么意思疾病动态疾病动态复发性/耐火性DLBCLL的情况挽救化学疗法的废弃物

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...